• Consensus Rating: Hold
  • Consensus Price Target: $171.22
  • Forecasted Upside: 22.98 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.52 (-1.78%)

This chart shows the closing price for PKI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PerkinElmer Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PKI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PKI

Analyst Price Target is $171.22
▲ +22.98% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for PerkinElmer in the last 3 months. The average price target is $171.22, with a high forecast of $205.00 and a low forecast of $145.00. The average price target represents a 22.98% upside from the last price of $139.23.

This chart shows the closing price for PKI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 investment analysts is to hold stock in PerkinElmer. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2022BarclaysUpgradeUnderweight ➝ Equal Weight$130.00 ➝ $145.00Low
11/14/2022Credit Suisse GroupLower TargetNeutral$175.00 ➝ $160.00Low
11/9/2022Robert W. BairdLower Target$202.00 ➝ $178.00Low
10/6/2022BarclaysLower TargetUnderweight$140.00 ➝ $120.00Low
9/12/2022BarclaysLower TargetUnderweight$149.00 ➝ $140.00Low
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$175.00Low
8/18/2022Stifel NicolausDowngradeBuy ➝ Hold$190.00 ➝ $170.00Low
8/2/2022BarclaysBoost TargetUnderweight$125.00 ➝ $149.00Low
8/2/2022Robert W. BairdBoost TargetOutperform$198.00 ➝ $202.00Low
8/2/2022Bank of AmericaDowngradeBuy ➝ Neutral$178.00Low
7/20/2022UBS GroupInitiated CoverageBuy$160.00Low
7/14/2022The Goldman Sachs GroupLower TargetNeutral$200.00 ➝ $175.00Low
5/17/2022BarclaysInitiated CoverageUnderweight$125.00Medium
5/4/2022Robert W. BairdLower Target$216.00 ➝ $198.00High
5/4/2022CitigroupLower Target$185.00 ➝ $170.00High
12/16/2021The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$200.00High
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$200.00 ➝ $205.00High
11/17/2021Royal Bank of CanadaBoost TargetOutperform$49.00 ➝ $50.00Medium
11/3/2021Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $200.00High
11/3/2021Robert W. BairdBoost TargetHold ➝ Outperform$183.00 ➝ $206.00High
8/9/2021Royal Bank of CanadaBoost TargetOutperform$48.00 ➝ $49.00Medium
7/27/2021Evercore ISIReiterated RatingOutperform$174.00 ➝ $170.86Medium
7/27/2021Robert W. BairdReiterated RatingOutperform$150.00 ➝ $172.11Medium
6/15/2021Wolfe ResearchUpgradeMarket Perform ➝ OutperformLow
2/3/2021CitigroupBoost Target$150.00 ➝ $155.00High
1/7/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $175.00N/A
12/11/2020Smith Barney CitigroupBoost Target$140.00 ➝ $150.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
11/12/2020The Goldman Sachs GroupInitiated CoverageBuy$50.00Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$150.00Medium
11/9/2020Needham & Company LLCBoost TargetBuy$139.00 ➝ $193.00High
10/29/2020Smith Barney CitigroupBoost Target$120.00 ➝ $140.00Low
10/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$130.00 ➝ $140.00Low
10/29/2020Robert W. BairdBoost TargetOutperform$137.00 ➝ $151.00High
9/11/2020Needham & Company LLCUpgradeHold ➝ Buy$139.00High
8/10/2020BMO Capital MarketsBoost TargetOutperform$44.00 ➝ $45.00Low
7/29/2020JPMorgan Chase & Co.Boost TargetNeutral$85.00 ➝ $105.00High
7/29/2020Stifel NicolausBoost TargetBuy$95.00 ➝ $125.00High
7/29/2020Wells Fargo & CompanyBoost TargetEqual Weight$105.00 ➝ $130.00High
7/29/2020CfraUpgradeHold ➝ BuyHigh
7/13/2020Needham & Company LLCInitiated CoverageHoldHigh
5/7/2020UBS GroupBoost TargetNeutral$95.00 ➝ $96.00Low
5/6/2020Robert W. BairdBoost TargetOutperform$94.00 ➝ $99.00Low
5/6/2020CfraLower TargetHold$100.00 ➝ $94.00Low
5/6/2020JPMorgan Chase & Co.Boost TargetNeutral$80.00 ➝ $85.00Medium
4/28/2020UBS GroupLower TargetNeutral$100.00 ➝ $95.00Low
4/20/2020CitigroupBoost TargetNeutral$70.00 ➝ $85.00Low
4/2/2020JPMorgan Chase & Co.Lower TargetOverweight$49.00 ➝ $45.00High
4/2/2020Stifel NicolausLower TargetBuy$102.00 ➝ $80.00Low
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$100.00 ➝ $80.00Low
3/26/2020BarclaysLower TargetEqual Weight$100.00 ➝ $94.00Medium
3/20/2020CitigroupLower TargetNeutral$100.00 ➝ $70.00Low
1/28/2020UBS GroupBoost TargetNeutral$92.00 ➝ $100.00High
1/14/2020TD SecuritiesBoost TargetBuy$54.00 ➝ $56.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$105.00Low
1/6/2020CitigroupInitiated CoverageNeutral$100.00Medium
1/3/2020Needham & Company LLCInitiated CoverageHold$79.00Medium
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$89.00 ➝ $114.00High
11/21/2019Stifel NicolausReiterated RatingBuyLow
11/14/2019Stifel NicolausInitiated CoverageBuy$102.00High
11/5/2019Raymond JamesReiterated RatingBuy ➝ Average$51.00Low
10/31/2019Needham & Company LLCReiterated RatingHoldHigh
10/31/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$104.00 ➝ $89.00High
10/18/2019UBS GroupLower TargetNeutral$101.00 ➝ $92.00Low
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$105.00Low
7/30/2019UBS GroupBoost TargetNeutral$99.00 ➝ $101.00High
7/19/2019Wood & CompanyReiterated RatingAverage$49.00Medium
7/10/2019Raymond JamesInitiated CoverageOutperformLow
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/3/2019Royal Bank of CanadaReiterated RatingHold$41.00Low
4/9/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00High
2/2/2019UBS GroupSet TargetHold$92.00Low
2/1/2019Piper Jaffray CompaniesBoost TargetOverweight$104.00Medium
1/16/2019DesjardinsReiterated RatingBuy ➝ Average$45.00Low
1/10/2019CIBCReiterated RatingBuy ➝ Average$44.50Medium
1/6/2019CowenReiterated RatingHold$85.00Low
1/3/2019Morgan StanleyLower TargetOverweight ➝ Overweight$100.00 ➝ $86.00Low
1/2/2019Needham & Company LLCInitiated CoverageHold ➝ Hold$79.00High
11/2/2018Janney Montgomery ScottDowngradeBuy ➝ NeutralMedium
10/10/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$95.00 ➝ $100.00High
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$100.00Low
9/10/2018Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$88.00 ➝ $93.00Low
9/5/2018BarclaysUpgradeUnderweight ➝ Equal Weight$79.00 ➝ $90.00Low
8/2/2018Bank of AmericaBoost TargetNeutral ➝ Neutral$83.00 ➝ $86.00Low
8/2/2018CowenReiterated RatingHold$85.00Low
8/2/2018Robert W. BairdReiterated RatingBuy$89.00Low
8/2/2018BarclaysBoost TargetUnderweight ➝ Underweight$73.00 ➝ $79.00High
8/2/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$90.00 ➝ $95.00High
5/1/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$85.00 ➝ $90.00High
5/1/2018Bank of AmericaLower TargetNeutral ➝ Hold$86.00 ➝ $83.00High
5/1/2018Robert W. BairdLower TargetOutperform ➝ Outperform$88.00 ➝ $82.00High
5/1/2018Janney Montgomery ScottLower TargetBuy ➝ Fair Value$92.00 ➝ $73.36High
4/11/2018Morgan StanleyLower TargetOverweight ➝ Overweight$89.00 ➝ $85.00Low
4/9/2018Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$85.00 ➝ $80.00Low
1/26/2018BarclaysBoost TargetUnderweight ➝ Underweight$69.00 ➝ $73.00Low
1/26/2018CowenReiterated RatingHold$84.00Low
1/26/2018Robert W. BairdReiterated RatingBuy$88.00Medium
1/3/2018Evercore ISIInitiated CoverageIn-Line$77.00Low
12/19/2017Bank of AmericaUpgradeUnderperform ➝ Neutral$78.00Low
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
PerkinElmer logo
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $139.23
Low: $138.66
High: $140.60

50 Day Range

MA: $130.91
Low: $117.01
High: $143.46

52 Week Range

Now: $139.23
Low: $113.46
High: $203.16


558,319 shs

Average Volume

916,188 shs

Market Capitalization

$17.57 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of PerkinElmer?

The following Wall Street analysts have issued stock ratings on PerkinElmer in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Robert W. Baird, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for PKI.

What is the current price target for PerkinElmer?

9 Wall Street analysts have set twelve-month price targets for PerkinElmer in the last year. Their average twelve-month price target is $171.22, suggesting a possible upside of 23.0%. Wells Fargo & Company has the highest price target set, predicting PKI will reach $205.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $145.00 for PerkinElmer in the next year.
View the latest price targets for PKI.

What is the current consensus analyst rating for PerkinElmer?

PerkinElmer currently has 5 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PKI, but not buy more shares or sell existing shares.
View the latest ratings for PKI.

What other companies compete with PerkinElmer?

How do I contact PerkinElmer's investor relations team?

PerkinElmer's physical mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company's listed phone number is (781) 663-6900 and its investor relations email address is [email protected] The official website for PerkinElmer is www.perkinelmer.com. Learn More about contacing PerkinElmer investor relations.